Why the study?
Do direct oral anticoagulants improve morbidity, mortality, and bleeding outcomes compared to warfarin in patients with chronic thromboembolic pulmonary hypertension?
Do direct oral anticoagulants improve morbidity, mortality, and bleeding outcomes compared to warfarin in patients with chronic thromboembolic pulmonary hypertension?
In patients with chronic thromboembolic pulmonary hypertension, DOACs provide similar prevention of morbidity and mortality as warfarin but with a lower rate of clinically relevant bleeding.
Supports considering DOACs to minimize bleeding in CTEPH; leaves open definitive recommendations without randomized evidence.
This registry demonstrated that under current standard of care, morbidity and mortality events were effectively prevented regardless of anticoagulants, while the clinically relevant bleeding rate was lower when using DOACs compared with warfarin.
No takes yet. Share an insight, caveat, or question.
Hosokawa et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: